{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-021032","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.402313+00:00","generated_at":"2026-05-20T02:41:01.984338+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PDS Biotech reports durable 30.0-month median OS from VERSATILE-002 in HPV16+ HNSCC","bullets":["Median overall survival (mOS) steady at 30.0 months with ~4.5 months additional follow-up; lower 95% CI increased to 23.9 months.","Median PFS: 6.3 months; ORR: 35.8%; disease control rate: 77.4%; median DoR: 21.8 months.","VERSATILE-003 is the only ongoing Phase 3 trial specifically addressing 1L r/m HPV16-positive HNSCC.","Data presented at ASCO 2025; no new safety signals; 22 of 53 patients still being followed."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-021032","json":"https://secwatch.observer/filing/0001140361-25-021032.json","markdown":"https://secwatch.observer/filing/0001140361-25-021032.md","text":"https://secwatch.observer/filing/0001140361-25-021032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125021032/0001140361-25-021032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125021032/ef20050049_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:41:01.984338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}